Eloxx Pharmaceuticals (NASDAQ:ELOX) Issues Earnings Results

Eloxx Pharmaceuticals (NASDAQ:ELOX) released its earnings results on Tuesday. The company reported ($0.66) EPS for the quarter, Zacks reports.

Eloxx Pharmaceuticals Trading Up 12.8%

ELOX stock opened at $19.18 on Wednesday. Eloxx Pharmaceuticals has a twelve month low of $8.20 and a twelve month high of $19.96. The company has a market cap of $13.23 million, a price-to-earnings ratio of -1.25 and a beta of -1,864.08. The company’s 50 day moving average is $15.79.

Analyst Ratings Changes

ELOX has been the subject of several research analyst reports. Guggenheim began coverage on Eloxx Pharmaceuticals in a research note on Monday, July 20th. They set a “buy” rating and a $43.00 price target for the company. Lifesci Capital started coverage on Eloxx Pharmaceuticals in a report on Wednesday, July 22nd. They set an “outperform” rating and a $40.00 price objective on the stock. Finally, Wall Street Zen raised shares of Eloxx Pharmaceuticals to a “hold” rating in a research note on Saturday, August 1st. Two analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $41.50.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.